Who
David Piacquad
Director
Company insider
Files Form 4 as: Director, Neumora Therapeutics; SVP, Business Development, Amgen.
In numbers
- Trades disclosed
- 82
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $2.1M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 25 Apr 2014
- Last trade
- 27 May 2026
- Last filed
- 29 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 27 May 2026filed 29 May 2026 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —80,000 at $0.00 | filing |
| 27 May 2026filed 29 May 2026 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —80,000 at $0.00 | filing |
| 28 May 2025filed 30 May 2025 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —46,455 | filing |
| 28 May 2025filed 30 May 2025 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —28,571 | filing |
| 28 May 2025filed 30 May 2025 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —46,455 | filing |
| 28 May 2025filed 30 May 2025 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —28,571 | filing |
| 28 May 2025filed 30 May 2025 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —80,000 at $0.00 | filing |
| 13 Feb 2025filed 18 Feb 2025 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —46,455 | filing |
| 13 Feb 2025filed 18 Feb 2025 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —28,571 | filing |
| 13 Feb 2025filed 18 Feb 2025 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —46,455 | filing |
| 13 Feb 2025filed 18 Feb 2025 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —28,571 | filing |
| 13 Jun 2024filed 14 Jun 2024 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —28,571 at $0.00 | filing |
| 13 Jun 2024filed 14 Jun 2024 | NMRA Neumora TherapeuticsBiotechnology | SEC FORM 4 Code A | —20,100 at $0.00 | filing |
| 14 Sep 2023filed 18 Sep 2023 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —46,455 at $0.00 | filing |
| 3 May 2021filed 4 May 2021 | AMGN AmgenBiotechnology | SEC FORM 4 Code F | $53K220 at $239.64 | filing |
| 1 May 2021filed 4 May 2021 | AMGN AmgenBiotechnology | SEC FORM 4 Code F | $33K139 at $239.64 | filing |
| 30 Apr 2021filed 4 May 2021 | AMGN AmgenBiotechnology | SEC FORM 4 Code A | —709 at $0.00 | filing |
| 30 Apr 2021filed 4 May 2021 | AMGN Amgenoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,159 at $0.00 | filing |
| 27 Apr 2021filed 28 Apr 2021 | AMGN AmgenBiotechnology | SEC FORM 4 Code F | $33K128 at $255.52 | filing |
| 19 Mar 2021filed 22 Mar 2021 | AMGN AmgenBiotechnology | SEC FORM 4 Code F | $242K991 at $244.42 | filing |
News
Amgen Has the Drugs and the Dividend. Now It Needs the GrowthAMGN · insidermonkey.com · 19 Oct 2026Biogen (BIIB) vs Amgen (AMGN) and Gilead (GILD): Which Big Pharma Stock is a Better Buy?AMGN · insidermonkey.com · 13 Oct 2026Amgen (AMGN) and Johnson & Johnson (JNJ) Catch Jim Cramer's Eye for Different ReasonsAMGN · insidermonkey.com · 8 Oct 2026
0 headlines in the last 90 days name David Piacquad; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.